Francois Ravenelle, Angel Investor

François Ravenelle is President and CEO of Innospera Pharma, a biotechnology company developing small-molecule GPCR modulators for chronic and fibrotic diseases. He is also President of Tarock Capital, a role he began in 2024, and serves as a Board Member at Noa Therapeutics. Previously, he was President and CEO of Inversago Pharma from 2016 to 2024, where he led development in metabolic and fibrotic disease therapeutics. As an investor, Ravenelle participated in the venture round for Aplantex in May 2026, contributing to a CA$5M raise.